• Patients

    Learn more about our LuCED® lung test, VisionGate’s non-invasive diagnostic test to aid physicians in the early detection of l...


    Learn more

  • Physicians

    The LuCED® lung test is a non-invasive, cost-effective test to precede, supplement or follow low-dose CT scans.


    Learn more

  • Researchers

    VisionGate has ongoing research opportunities and continues to grow its team of collaborative partners from around the world.


    Learn more



Announcements

VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug

Press Release, August 22, 2019

more

VisionGate Announces Lung Cancer Prevention Trial Progress and PCI Pharma Services Manufacturing Agreement

Press Release, January 29, 2019

more

VisionGate, Inc. Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors

Press Release, October 11, 2018

more

Recent News



Copyright 2019 - VisionGate, Inc.